Introduction This study aims to predict recurrence-free survival (RFS) and overall survival (OS), to stratify risk using radiomics, radiology semantic, clinical, and pathology models—individually and in combination—derived from pre-treatment magnetic resonance imaging (MRI), post-operative histopathology, age, and adju...
N. Chakrabarty, S. Rane, U. Sherkhane et al.· Frontiers in Oncology· 1 citation
KRAS-mutant NSCLC is transitioning from historically untargetable disease to a therapeutically actionable subset, and future progress hinges on resistance-directed combinations, biomarker-guided personalization, expansion to non-G12C mutants, and evaluation in earlier disease settings.
A. Kapoor, Bipinesh Sansar, Anuj Gupta et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.